KARYOPHARM THERAPEUTICS INC stock forecast: down to 1.24 USD KPTI stock price prognosis


Forecast for Wed 12 Jun 2024 price 1.27

KARYOPHARM THERAPEUTICS INC stock price forecast for further price development down to -10.55% (time horizon: 1 day) and price target of 1.24 USD. Short-term (time horizon: 2 weeks) KARYOPHARM THERAPEUTICS INC share price prediction for 2024-06-12 with daily closed price projections

Key Facts

Symbol KPTI 

ISIN US48576U1060 

CUSIP 48576U106

Currency USD

Category Pharmaceutical Preparations

Forecast price change %

Relative Strength Index (RSI)

Finance numbers

Revenue 113,207,000.0

Earnings per share -2.71

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

We refer to myeloma that is refractory to these five agents as penta-refractory. 8226; Dosed first patient in June 2020 in the XPORT-GBM-029 Study. A membrane, called the nuclear membrane, separates the nucleus from the cytoplasm. Key clinical trials of selinexor are summarized in the charts below. Serious adverse reactions occurred in 52% of patients who received XVd. Treatment discontinuation rate due to adverse reactions was 27%. 2 Based on interim unaudited data. The median PFS was 23.7 months for all patients. In this population, XPOVIO demonstrated an ORR of 29%, including a CR rate of 13%. In June 2020, we dosed the first patient in this study. Any patents issued in foreign jurisdictions will likewise expire in 2040. There are four issued U.S. patents that cover verdinexor. In many cases, these drugs are administered in combination to enhance efficacy. The FDA may request additional information rather than accept an NDA for filing. The Regulation was published on June 16, 2014 but has not yet become effective. The website indicated that the audit was expected to commence in December 2020. Coverage policies and third-party reimbursement rates may change at any time. As of February 16, 2021, we had 432 employees. Mr. Frenkel received a BPharm from Hebrew University. These confirmatory trials must be completed with due diligence. Similar restrictions apply to the approval of our products in the EU. We may not be able to obtain orphan drug exclusivity for our product candidates. The applicable period is seven years in the U.S. and ten years in Europe. Thereafter, the U.S. Supreme Court agreed to hear this case. Infringement of these laws could result in substantial fines and imprisonment. Our net loss was $196.3 million for the year ended December 31, 2020. We will need additional funding to achieve our business objectives. We may also incur additional indebtedness to meet future financing needs. In these cases, our business could be materially harmed. All contain numerous tax provisions.

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1503802/000119312521054811/0001193125-21-054811.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 26.04/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
A - BARCLAYS PLC 2023-06-30 1106361
A - OSAIC HOLDINGS, INC. 2023-06-30 7079
China Universal Asset Management Co., Ltd. 2023-06-30 1494
MetLife Investment Management, LLC 2022-12-31 29394

Fund ownership list is based on filling form information

Fund name Date Amount Profile
ProShares Trust 2023-11-30 7575 Long
ProShares Trust 2023-11-30 9127 Long
ProShares Trust 2023-11-30 5253 Long
ProShares Trust 2023-11-30 257 Long


CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1865796 Cheng Sohanya Roshan 2024-02-29 SALE Accept Accept Accept Accept
1804460 Paulson Richard A. 2024-04-04 SALE Accept Accept Accept Accept
1514291 Mason Michael 2024-03-01 SALE Accept Accept Accept Accept
1837741 Mano Michael 2024-02-29 SALE Accept Accept Accept Accept
1942597 Poulton Stuart 2024-02-29 SALE Accept Accept Accept Accept
1825322 Rangwala Reshma 2024-02-29 SALE Accept Accept Accept Accept

Bollinger Bollinger Bands for KARYOPHARM THERAPEUTICS INC can provide the information where the market is moving based on price information.

KARYOPHARM THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns KARYOPHARM THERAPEUTICS INC.

On-Balance Volume information for KARYOPHARM THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for KARYOPHARM THERAPEUTICS INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for KARYOPHARM THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for KARYOPHARM THERAPEUTICS INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for KARYOPHARM THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for KARYOPHARM THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for KARYOPHARM THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

Heikin Ashi trading signals are generated based on the Heikin Ashi candles, which are a type of candlestick that smooths out the price action and can help to identify trends. Heikin Ashi signals can be used to identify both long and short trading opportunities.

The awesome oscillator is a momentum indicator that measures the speed and strength of price movements. It is calculated by subtracting a 34-period simple moving average (SMA) from a 5-period SMA.

The Parabolic SAR indicator is a trend-following indicator that uses a series of dots to indicate when a trend is likely to reverse. The Parabolic SAR is a lagging indicator, meaning that it does not predict reversals, but rather confirms them after they have already occurred.

Moving Average Crossover

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2024-05-20 1.24 2024-04-17 10:15
2024-05-21 1.25 2024-04-17 10:15
2024-05-23 1.25 2024-04-17 10:15
2024-05-24 1.25 2024-04-17 10:15
2024-05-22 1.25 2024-04-17 10:15
2024-05-27 1.25 2024-04-17 10:15
2024-05-28 1.25 2024-04-17 10:15
2024-06-07 1.26 2024-04-17 10:15
2024-06-05 1.26 2024-04-17 10:15
2024-05-30 1.25 2024-04-17 10:15
2024-06-03 1.26 2024-04-17 10:15
2024-06-04 1.26 2024-04-17 10:15
2024-05-31 1.26 2024-04-17 10:15
2024-05-29 1.25 2024-04-17 10:15
2024-06-10 1.27 2024-04-17 10:15
2024-06-06 1.26 2024-04-17 10:15
2024-05-01 1.21 2024-04-17 10:15
2024-05-03 1.23 2024-04-17 10:15
2024-06-11 1.27 2024-04-17 10:15
2024-06-12 1.27 2024-04-17 10:15
2024-05-15 1.25 2024-04-17 10:15
2024-05-07 1.21 2024-04-17 10:15
2024-05-08 1.22 2024-04-17 10:15
2024-05-09 1.24 2024-04-17 10:15
2024-04-19 1.16 2024-04-17 10:15
2024-05-16 1.25 2024-04-17 10:15
2024-04-24 1.15 2024-04-17 10:15
2024-04-25 1.17 2024-04-17 10:15
2024-04-18 1.13 2024-04-17 10:15
2024-05-17 1.24 2024-04-17 10:15
2024-04-26 1.19 2024-04-17 10:15
2024-05-10 1.24 2024-04-17 10:15
2024-04-22 1.18 2024-04-17 10:15
2024-04-23 1.16 2024-04-17 10:15
2024-04-29 1.17 2024-04-17 10:15
2024-04-30 1.18 2024-04-17 10:15
2024-05-02 1.21 2024-04-17 10:15
2024-05-06 1.20 2024-04-17 10:15
2024-05-13 1.24 2024-04-17 10:15
2024-05-14 1.25 2024-04-17 10:15

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.